CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2009-10-01): "Substantial" toxicity with peginterferon use: FDA staff


"Substantial" toxicity with peginterferon use: FDA staff

Last Updated: 2009-10-01 19:30:14 -0400 (Reuters Health)

WASHINGTON (Reuters) - Schering-Plough Corp's injectable drug PegIntron (peginterferon) carries "substantial toxicity" and had no effect on overall survival in melanoma skin cancer patients undergoing surgery, U.S. Food and Drug Administration staff reviewers said in documents released on Thursday.

Schering is seeking FDA approval to sell PegIntron for use with surgery in cases where the melanoma has spread to the lymph nodes.

PegIntron is already approved for liver disease in conjunction with the company's Rebetol (ribavirin) for chronic hepatitis C.

The FDA released the documents ahead of an advisory committee meeting on Monday to discuss whether to approve the drug. The agency usually takes the advice of its outside experts.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.